Exiqon A/S

Exiqon launches ExiLERATE LNA™ qPCR product portfolio for analysis of mRNA and lncRNA

Exiqon integrates RNAseq workflow in unique cloud-computing environment, XploreRNA™

Exiqon launches new LNA™ antisense oligonucleotides for RNA functional analysis

Q1 2015 WAS THE BEST QUARTER EVER FOR EXIQON

Exiqon launches Next Generation Sequencing services for microRNAs in blood

Exiqon A/S – Decisions at the annual general meeting 2015

Announcement No. 2/2015

Announcement of management’s and closely related parties’ transactions with securities in Exiqon A/S

FULL YEAR RESULTS 2014

Exiqon launches two new Research Use Only kits for PCR analysis of colon cancer samples.

Exiqon licenses validated biomarkers for prostate cancer from Aarhus University Hospital.

Exiqon A/S announces financial calendar for 2015

INTERIM REPORT FOR THE PERIOD 1 JANUARY – 30 SEPTEMBER 2014 (UNAUDITED)

Redefining high risk patients with stage II colon cancer

INTERIM REPORT FOR THE PERIOD 1 JANUARY – 30 June 2014 (UNAUDITED)

Exiqon launches XploreRNA™ app for advanced cross-database queries

Exiqon launches Exosome Isolation kits for analysis of biofluids

INTERIM REPORT FOR THE PERIOD 1 JANUARY – 31 MARCH 2014

Exiqon A/S – Decisions at annual general meeting 2014

Exiqon calls for ordinary general meeting on 25 March 2014

Full year results for 2013

Exiqon releases new online search tool for gene expression studies

Exiqon launches Next Generation Sequencing services

Major shareholder announcement

Exiqon Announces 2014 Grant Program for microRNA, long non-coding RNA or mRNA research

REVISED FINANCIAL OUTLOOK 2013 DUE TO TEMPORARY SUPPLY ISSUES

Exiqon launches qPCR Array product for custom designed microRNA, mRNA and lncRNA assays

Exiqon A/S announces financial calendar for 2014

INTERIM REPORT FOR THE PERIOD 1 JANUARY – 30 SEPTEMBER 2013 (UNAUDITED)

Exiqon launches advanced on-line tool for design of LNA™ gapmers for inhibition of mRNA and lncRNA